Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes

Milena Rondón-Lagos¹, Nelson Rangel¹-², Ludovica Verdun Di Cantogno³, Laura Annaratone¹, Isabella Castellano¹, Rosalia Russo¹, Tilde Manetta⁴, Caterina Marchiò¹,* and Anna Sapino¹,5,*

¹Department of Medical Sciences, University of Turin, Turin, Italy
²Natural and Mathematical Sciences Faculty, Universidad del Rosario, Bogotá, Colombia
³Pathology Division, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy
⁴Department of Public Health and Pediatrics, University of Turin, Turin, Italy
⁵Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
*(C Marchiò and A Sapino contributed equally to this work)

Abstract

Evidence supports a role of 17β-estradiol (E₂) in carcinogenesis and the large majority of breast carcinomas are dependent on estrogen. The anti-estrogen tamoxifen (TAM) is widely used for both treatment and prevention of breast cancer; however, it is also carcinogenic in human uterus and rat liver, highlighting the profound complexity of its actions. The nature of E₂- or TAM-induced chromosomal damage has been explored using relatively high concentrations of these agents, and only some numerical aberrations and chromosomal breaks have been analyzed. This study aimed to determine the effects of low doses of E₂ and TAM (10⁻⁸ mol L⁻¹ and 10⁻⁶ mol L⁻¹ respectively) on karyotypes of MCF7, T47D, BT474, and SKBR3 breast cancer cells by comparing the results of conventional karyotyping and multi-FISH painting with cell proliferation. Estrogen receptor (ER)-positive (+) cells showed an increase in cell proliferation after E₂ treatment (MCF7, T47D, and BT474) and a decrease after TAM treatment (MCF7 and T47D), whereas in ER- cells (SKBR3), no alterations in cell proliferation were observed, except for a small increase at 96h. Karyotypes of both ER+ and ER- breast cancer cells increased in complexity after treatments with E₂ and TAM leading to specific chromosomal abnormalities, some of which were consistent throughout the treatment duration. This genotoxic effect was higher in HER2+ cells. The ER-/HER2+ SKBR3 cells were found to be sensitive to TAM, exhibiting an increase in chromosomal aberrations. These in vitro results provide insights into the potential role of low doses of E₂ and TAM in inducing chromosomal rearrangements in breast cancer cells.

Introduction

17β-estradiol (E₂) is the main estrogenic hormone that through the estrogen receptors (ER) acts on the mammary gland regulating a wide variety of biological processes including differentiation, cell proliferation, and development at puberty and during sexual maturity. E₂ may be procarcinogenic by inducing (i) ER-mediated cell proliferation, (ii) gene mutation through a cytochrome P450-mediated metabolic activation, and (iii) aneuploidy.
(Russo & Russo 2006), through overexpression of Aurora-A (Aur-A), a centrosome kinase, and centrosome amplification (Li et al. 2004). In addition, in both ER+ and ER− breast cancer cells, E2 may induce chromatin structural changes through the estrogen-related receptors (ERR) (Hu et al. 2008). Although high levels of E2 are implicated in breast cancer in postmenopausal women (Bernstein & Ross 1993), constant low E2 concentrations, in the range of picograms, are sufficient to increase breast cancer risk in premenopausal women (Chetrite et al. 2000).

Tamoxifen (TAM) is a non-steroidal anti-estrogen with partial agonistic activity, extensively used in the treatment of ERα-positive breast cancer. Response to TAM is frequently of limited duration due to the development of resistance (Pearce & Jordan 2004, International Breast Cancer Study et al. 2006). Although ERα positivity is a well-established predictor of response to TAM and ERα-negative patients are considered nonresponders, it is known that 5–10% of ERα-negative tumors do benefit from adjuvant TAM treatment (McGuire 1975, Early Breast Cancer Trialists’ Collaborative Group 1992, 1998, Early Breast Cancer Trialists’ Collaborative Group et al. 2011, Gruvberger-Saal et al. 2007).

Paradoxically, it has been reported that TAM possesses a high mutagenic potential causing chromosome ruptures in animal models (Mizutani et al. 2004). However, data on type and frequency of chromosome abnormalities induced by TAM are scant (Mizutani et al. 2004). In particular, cytogenetic studies about the effects of low doses of TAM, as it is suggested for treatment of pre-invasive low-grade breast lesions (e.g., low-grade ductal carcinomas in situ or lobular intraepithelial neoplasia), are limited (Kedia-Mokashi et al. 2010). The nature of E2− or TAM-induced chromosomal damage has been explored using relatively high concentrations of these agents, and only some numerical aberrations and chromosomal breaks have been analyzed (Tutsui & Barrett 1997, Mizutani et al. 2004, Quick et al. 2008, Kedia-Mokashi et al. 2010).

The aim of this study was to determine the effects of low doses of E2 and TAM on chromosomal rearrangements by comparing the results of conventional karyotyping and multicolor fluorescence in situ hybridization (M-FISH) painting with cell proliferation activity of human breast cancer cells with differential expression of ER and HER2.

**Materials and methods**

**Cell lines**

The human breast cancer cell lines MCF7 and T47D (ER+/progesterone receptor (PR)+/HER2−), BT474 (ER+/PR+/HER2+), and SKBR3 (ER−/PR−/HER2+) were obtained from the American Type Culture Collection (ATCC) in March 2010. Cell lines were expanded and stocked at −80°C and cells obtained from these stocks were thawed and used for the experiments. At the end of experiments, short tandem repeat (STR) profiles were performed to confirm the authentication of the cell lines used. All experiments were carried out in each cell line at passages (P) below 30.

MCF7 (P19), T47D (P20), and SKBR3 (P16) were cultured in RPMI-1640 medium (Sigma), whereas BT474 (P18) was cultured in DMEM medium (Sigma). All culture media were supplemented with 10% fetal bovine serum (FBS) (Sigma), antibiotic–antimycotic solution (1X) (Sigma), and l-glutamine (2 mM) (Invitrogen GmbH). Cells growing in 75 cm² flasks were maintained at 37°C and 5% CO₂. The absence of contamination with mycoplasma was demonstrated by PCR assay.

**E₂ and TAM treatment**

In order to remove endogenous serum steroids and exclude the weak estrogen agonistic activity of phenol red (Berthois et al. 1986), 48 h before the addition of E2 (E2758; Sigma) and TAM (T5648; Sigma) cells were washed with 5 mL phosphate-buffered saline (PBS) and then switched to phenol red-free RPMI-1640 (Sigma) containing 10% charcoal-stripped FBS (Sigma). E2 and TAM were dissolved in absolute ethanol and diluted in the media at 10⁻⁸molL⁻¹ and 10⁻⁶molL⁻¹, respectively, and then added to the culture medium at 24, 48, and 96 h. These concentrations have been demonstrated to be the lowest to induce an effect on the architecture of the cytoskeleton in breast cancer cells in vitro (Sapino et al. 1986).

Cells without treatment at 24 h (T24 h) and at 96 h (T96 h) were used as controls.

**Proliferation assay**

Cells were seeded at a density of 2.5–5×10⁴ cells per 100 μL of phenol red-free medium in a 96 multi-well plate and after 24 h were treated with E2 and TAM for 24, 48, and 96 h. At the end of each treatment, cell proliferation was assessed using the cell proliferation ELISA kit, BrdU (Roche Diagnostics Deutschland GmbH). Measurement of absorbance was performed by using a Multiskan Bichromatic reader (Labsystems, Midland, Canada) against a background control as blank. Each treatment was performed in 24 replicates and expressed as means±standard deviation (S.D.).
Metaphase spreads and G-banding

To determine whether E2 and TAM treatment resulted in the induction of chromosomal abnormalities, we performed conventional and molecular cytogenetic analysis in parallel with the evaluation of cell proliferation. Metaphases were obtained by using standardized harvesting protocols in order to perform conventional and molecular cytogenetic analysis (multi-FISH and FISH). Briefly, colcemid solution (0.03 μg/mL) (Sigma) was added to cultures 2.5 h before cell harvesting; cells were then treated with hypotonic solution, fixed three times with Carnoy’s fixative (3:1 methanol to acetic acid), and spread on glass. For analysis of chromosomal alterations, the slides were banded with G-banding. Glass slides were baked at 70°C for 24 h before cell harvesting; cells were then treated with Wright’s stain. Metaphase image acquisition and subsequent karyotyping were performed using a Nikon microscope with the cytogenetic software CytoVision System (Applied Imaging, Santa Clara, CA, USA). According to the International System of Cytogenetic Nomenclature (Shaffer et al. 2013) “The general rule in tumor cytogenetics is that only the clonal chromosomal abnormalities should be reported”, whereas a minimal number of metaphases to be analyzed is not indicated. In this respect, we indicated only those alterations present in at least two metaphases, which is indicative of clonal chromosomal alterations (Shaffer et al. 2013). Based on these premises, we systematically analyzed 100 metaphases in order to establish the frequency of ploidy after treatments, by counting the number of chromosomes. As a second step, out of these metaphases, only those with good morphology and proper separation of chromosomes were analyzed by M-FISH and G-banding (between 11 and 26). Chromosome aberrations were described according to the International System of Human Cytogenetic Nomenclature (ISCN 2013) (Shaffer et al. 2013).

Multi-FISH (M-FISH)

M-FISH was performed with the aim of identifying complex chromosomal rearrangements. The probe cocktail containing 24 differentially labeled chromosome-specific painting probes (24xCyte kit MetaSystems, Altlussheim, Germany) was used according to the protocol recommended by Human Multicolor FISH kit (MetaSystems, Altlussheim, Germany). Briefly, the slides were incubated at 70°C in saline solution (2xSSC), denatured in NaOH, dehydrated in ethanol series, air-dried, covered with 10 μL of probe cocktail (denatured), and hybridized for 2 days at 37°C. Slides were then washed with post-hybridization buffers, dehydrated in ethanol series, and counterstained with 10 μL of DAPI/antifade. Signal detection and subsequent metaphase analysis were done using the Metafer system and Metasytems’ ISIS software (software for spectral karyotypes) (Carl Zeiss, Metasystems, GmbH, Germany) (Rondon-Lagos et al. 2014a,b).

Immunohistochemistry (IHC)

Immunohistochemistry for ER and PR was carried out on MCF7, T47D, BT474, and SKBR3 cells at baseline and treated with E2 (10⁻⁸ mol L⁻¹) and TAM (10⁻⁶ mol L⁻¹) for 24, 48, and 96 h. At each time point, cells were harvested, formalin-fixed, and paraffin-embedded according to standard procedures. Sections of the representative cell block were cut at 3 μm and mounted on electrostatically charged slides. Immunohistochemistry was performed using an automated immunostainer (Ventana BenchMark XT AutoStainer; Ventana Medical Systems, Tucson, AZ, USA) with antibodies against ER (Clone SP1, prediluted, Ventana) and PR (Clone 1A6, 1:50 diluted; Leica Biosystems). Positive and negative controls were included for each immunohistochemical run. IHC slides were scanned by using the Aperio system (ScanScope CS System, Vista, CA, USA) for automated counting. To ensure the reliability of the automatic assessment, stainings were reviewed by two pathologists (A S and C M).

Data analysis

The profile of numeric and structural chromosomal changes observed after treatments was determined in comparison with the control. Student’s t-test was performed to compare cell proliferation of treated cell lines with untreated cell lines. Fisher’s exact test was applied to compare conventional and molecular cytogenetic results from treated cell lines with the results from control cell lines (differences in single chromosomal alterations between control and treated cells). In addition, Pearson’s χ² test was used to investigate a possible association between occurrence of specific chromosomal aberrations at each time point and effect on proliferation. The coefficient of variation, CV (=100 × standard deviation/mean), was used to calculate the variability in the frequency of new chromosomal alterations, observed after E2 and TAM treatments (24, 48, and 96 h). P values <0.05.
were considered as statistically significant. All statistical analyses were performed using the SPSS v.20 program.

**Results**

**General effects on chromosomes induced by low doses of E2 and TAM**

Control cells harbored the same alterations previously reported (Rondon-Lagos et al. 2014a,b). Both E2 and TAM treatments rapidly induced de novo chromosomal alterations.

The frequency of new chromosomal alterations changed along E2 and TAM treatments for all cell lines, and while the frequency of some chromosomal abnormalities remained constant along treatments, other increased or decreased (CV range: 3–96%) (Fig. 1 and Supplementary Table 1, see section on supplementary data given at the end of this article). This variability is not surprising, considering that genetic diversification, clonal expansion, and clonal selection are events widely reported in cancer and also associated with therapeutic interventions (Greaves & Maley 2012).

More in detail, compared with control cells (T24 h and T96 h without treatment), low doses of E2 increased the chromosome ploidy in all cell lines (Table 1A), whereas TAM was effective on ploidy only in HER2+ cell lines (Table 1B). Some of the alterations were observed in more than one cell line and were induced by both E2 and TAM (Fig. 2 and Supplementary Table 2). In Fig. 3, the chromosomal aberrations induced or increased after E2 or TAM treatments as compared with control cells are represented. Low doses of E2 produced

![Figure 1](http://dx.doi.org/10.1530/ERC-16-0078)

**Figure 1**

Frequency of chromosomal alterations observed de novo after E2 and TAM treatments. The frequency of each chromosomal alteration is indicated along the treatments (24, 48, and 96 h) using a color code for each category. (A) MCF7 cells. (B) T47D cells. (C) BT474 cells. (D) SKBR3 cells. A full colour version of this figure is available at http://dx.doi.org/10.1530/ERC-16-0078.
numerical alterations represented mainly by gain of whole chromosomes in all cell lines. Low doses of both E₂ and TAM induced de novo structural aberrations such as isochromosomes (i) in BT474 and SKBR3 cells and dicentric (dic) chromosomes in T47D and BT474 cells. Both treatments increased derivative (der) chromosomes in HER2+ cells only, whereas additional material of unknown origin (add) was a de novo observation only in T47D after E₂ treatment.

Many of the altered chromosomal regions in the cell lines analyzed contain important genes involved in breast cancerogenesis including BCAR3 (1p22), CENPF (1q41), ENAH (1q42), and AKT3 (1q44) associated with aneuploidy, chromosomal instability, and anti-estrogen resistance (Nakatani et al. 1999, Di Modugno et al. 2006, O’Brien et al. 2007); FHIT, FOXP1, and LRIG1 on 3p14 correlated with chromosomal instability and anti-estrogen resistance (Campiglio et al. 1999, Banham et al. 2001).
Breast cancer cell karyotypes, E2 and tamoxifen

Combined effects on cell proliferation and chromosomal alterations

We then more specifically analyzed the chromosomal alterations in comparison with the effects on proliferation induced by E2 and TAM in each cell line. Although we did not observe a specific pattern of chromosomal aberrations that significantly correlated with either increased or decreased proliferation rates across cell lines, single aberrations significantly correlated with increase or decrease of proliferation within each cell line, as detailed below.

In MCF7 cell line, as expected, E2 treatment significantly stimulated cell proliferation \((P<0.0001,\) Student’s t-test; Fig. 4A) and induced more structural than numerical chromosomal alterations \((P \leq 0.05,\) Fisher’s exact test; Fig. 2, Supplementary Tables 2, 3 and 4). However, only a statistically significant increase in nullisomy of chromosome 18 and 20 \((P < 0.01)\) together with del(7)(q21) and del(7)(q32) was constantly observed at all treatment time points (Figs 2 and 4A, Supplementary Tables 3 and 4).

TAM treatment inhibited significantly MCF7 cell proliferation \((P < 0.01)\) (Fig. 4B). Eleven chromosomes \((1, 2, 6, 7, 8, 10, 11, 17, 15, 19, \) and \(20)\) varied in their copy number, but most of these alterations, except for \(+1\) and \(-6\), were observed only in one of the treatment time points and were considered as sporadic (Supplementary Table 3). As compared with control cells, six additional complex chromosomal aberrations, del(1)(p21), del(3)(p13), der(7) t(7;20)(p22;q11.21)t(7;20)(p21;?), add(8)(p23), der(9)t(9;21)(p24;?) t(8;21)(q24;?), and der(11)t(4;11)(?;p15) (Figs 2, 4B, 5A and Supplementary Table 2), were identified and constantly present at each time point. In addition, der(11)t(4;11) (?;p15) was observed in both E2- and TAM-treated cells. An increase in the frequency of two pre-existing alterations del(7)(q11.2) and del(12)(p11.2) was also observed after both E2 and TAM treatment (Supplementary Table 4).

T47D cells responded to E2 treatment with the highest growth advantage at 96 h (Fig. 6A). This effect corresponded to a more complex karyotype of E2- stimulated cells than control cells with the following additional alterations, \(+3, -7, -8, \) der(11)t(4;11) (?;p15), \(-14, +16, \) and der(17)t(17;21)(q24;?) \((P < 0.01)\) observed at least at two time points (Figs 2, 5B, 6A and Supplementary Table 2). In analogy to MCF7 cells, an increase in the frequency of some pre-existing numerical alterations was observed after both treatments in T47D cells (Supplementary Table 5).

The effect of TAM on cell growth inhibition was much lower than that observed in MCF7 cells and disappeared at 96 h (Fig. 6B). As compared with untreated controls, only three additional numerical alterations were constantly present \((+6, -14, \) and \(-17)\) \((P < 0.01,\) Fisher’s exact test) after TAM (Fig. 6B, Supplementary Tables 5 and 6). On the contrary, some chromosomal rearrangements present in the control cells could not be observed after E2 and TAM treatment (Supplementary Table 6). In T47D, both E2 and TAM induced loss of chromosomes 7, 8, and 14, whereas an additional chromosome 19 was induced by both treatments in T47D and SKBR3 cells.

In BT474 cells, both E2 and TAM treatments induced two peaks of proliferation at 24 and 96 h. G-banding and M-FISH analyses of both E2- and TAM-treated BT474 cells identified the same new chromosomal complex rearrangements der(3)t(3;8)(p14;?), der(8)
Table 2  Selected breast cancer oncogenes and tumor suppressor genes present in the chromosomal regions affected by chromosomal abnormalities in MCF7, T47D, BT474, and SKBR3 cell lines following treatment with E2 and TAM for 24, 48, and 96 h.

| Chromosomal region | Genes | Cell line | Function |
|-------------------|-------|-----------|----------|
| 1p13.3            | CSF1  | X         | Cell proliferation |
| 1p22              | BCL10 | X X       | Oncogene, apoptosis |
| 1p22              | BCAR3 | X         | Cell proliferation, resistance in breast cancer cell lines |
| 1p32p31           | JUN   | X         | Oncogen |
| 1p36.21           | PRDM2 | X         | Tumor suppressor gene, binds to ER. Transcriptional regulation, E2 effector action |
| 1q11              | MUC1  | X         | Cell physiology and pathology, up-regulated in breast cancer |
| 1q21.1            | CA14  | X         | Basic cellular metabolism; breast cancer |
| 1q21.3            | PIP5K1A | X         | Cell proliferation, breast cancer |
| 1q25.2-q25.3      | COX2  | X         | Inflammation and mitogenesis |
| 1q32              | KISS  | X         | Cell motility, oncogene |
| 1q31              | PTGS2 | X         | Inflammation, tumorigenesis |
| 1q41              | CENPF | X         | Kinetochore assembly |
| 1q42.12           | ENAH  | X         | Cell shape and movement |
| 1q44              | AKT3  | X         | Proliferation, cell survival, and tumorigenesis |
| 3p14              | FHIT  | X         | Tumor suppressor gene; resistance to tamoxifen in MCF7 cells |
| 3p14              | FOXP1 | X         | Tumor suppressor gene, multiple types of cancers |
| 3p14              | LRG1  | X         | Suppressor of receptor tyrosine kinases, breast cancer |
| 6p25              | TFAP2A| X         | Tumor suppressor gene, breast cancer |
| 6p25              | DUSP22| X         | Signaling pathway, breast cancer |
| 7p22              | GPR30 | X         | G protein-coupled receptor 30, drug resistance |
| 7p22              | SDK1  | X         | Cell adhesion protein, breast cancer |
| 7q11.2            | LIMK1 | X         | Organization of actin cytoskeleton |
| 7q11.2            | HSPB1 | X         | Oncogenesis and resistance to various anti-cancer therapies |
| 7q11.2            | AUTS2 | X         | Breast cancer |
| 7q21              | AKAP9 | X         | Protein that assembles protein kinases on the centrosome |
| 7q21              | DMTF1 | X         | Transcriptional activator promoting p53/TP53-dependent growth arrest. |
| 7q32              | HIPK2 | X         | Tumor suppressor gene, breast cancer |
| 7q36              | MNX1  | X         | Transcription factor, breast cancer |
| 7q36              | MLL3  | X         | Transcriptional coactivation, breast cancer |
| 8p22              | MTUS1 | X X       | Tumor suppressor gene, breast cancer |
| 8p23              | CTSB  | X X       | Metabolism, angiogenesis, invasion, and metastasis in breast cancer |
| 8p23              | CSMD1 | X X       | Tumor suppressor gene, poor survival in breast cancer |

References:
- www.ncbi.nlm.nih.gov
- Lin (2009)
- Nakatani et al. (1999), Di Modugno et al. (2006), O'Brien et al. (2007)
- Zaretsky et al. (2006)
- Orsetti et al. (2006), Beroukhim et al. (2010), Bignell et al. (2010)
- Orsetti et al. (2006), Beroukhim et al. (2010), Bignell et al. (2010)
- Dossus et al. (2010)
- Nakatani et al. (1999), Di Modugno et al. (2006), O'Brien et al. (2007)
- Nakatani et al. (1999), Di Modugno et al. (2006), O'Brien et al. (2007)
- Campiglio et al. (1999)
- Banham et al. (2001)
- Ljuslinder et al. (2005)
- Scibetta et al. (2010)
- Curtis et al. (2012)
- Wang et al. (2010)
- Curtis et al. (2012)
- Laskowska et al. (2010)
- Laskowska et al. (2010)
- Edwards & Scott (2000)
- Sreeramaneni et al. (2005)
- Pierantoni et al. (2007)
- Nik-Zainal et al. (2012)
- Nik-Zainal et al. (2012)
- Rodrigues-Ferreira et al. (2009)
- Rafn et al. (2012)
- Kamal et al. (2010), Curtis et al. (2012)
| Chromosomal region | Genes | Cell line | Function | References |
|---------------------|-------|-----------|----------|------------|
| 8p23                | DLC1  | X         | Tumor suppressor gene, breast cancer | Popescu & Zimonjic (2002) |
| 9p24                | JAK2  | X         | Protein tyrosine kinase of the non-receptor type, breast cancer | Curtis et al. (2012) |
| 9p24                | RDN2  | X         | Development of mammary gland. Invasion in breast cancer | Radestock et al. (2008) |
| 9p24                | KANK1 | X         | Tumor suppressor gene, breast cancer | Curtis et al. (2012) |
| 9p24                | JMID2C| X         | Demethylase, breast cancer | Curtis et al. (2012) |
| 10p11.2             | AB1I  | X         | Cell growth inhibitor, cancer progression, and prognosis | Cui et al. (2010) |
| 11p15               | HRAS  | X         | Signal transduction, tumor aggressiveness in breast cancer | Hae-Young Yong et al. (2011) |
| 11p15               | CTS5  | X         | Invasion and metastasis | Lybong et al. (2012) |
| 11p15               | CD151 | X         | Signal transduction, breast cancer | Curtis et al. (2012) |
| 11p15               | RRM1  | X         | Tumor suppressor gene, DNA repair | Kim et al. (2011) |
| 11p15               | MMP26 | X         | Migration and angiogenesis, breast cancer | Curtis et al. (2012) |
| 11p15               | CDKN1C| X         | Negative regulator of cell cycle | www.ncbi.nlm.nih.gov |
| 11q23               | ATM   | X         | Tumor suppressor gene, DNA repair | Roy et al. (2006) |
| 11q23               | CRYAB | X         | Molecular chaperone function, metastasis in breast cancer | Lincon & Bove (2005) |
| 11q23               | ETS1  | X         | Transcription factor, breast cancer | Lundgren et al. (2008) |
| 11q23               | CCND1 | X         | Cell cycle G1/S transition, tumorigenesis in various carcinomas | Scintu et al. (2007) |
| 11q23               | PGR   | X         | Signal transduction, breast cancer | Kang et al. (2014) |
| 15q10               | BUB1B | X         | Mitotic spindle checkpoint, chromosomal instability in breast cancer | www.ncbi.nlm.nih.gov |
| 15q15               | THBS1 | X         | Invasion, metastasis, angiogenesis | Kang et al. (2014) |
| 15q26.3             | IGF1R | X         | Cell growth and survival control, breast cancer | www.ncbi.nlm.nih.gov |
| 17q24               | BIRC5 | X         | Apoptosis inhibition | Curtis et al. (2012), Nik-Zainal et al. (2012) |
| 18q21.1             | SMAD4 | X         | Transcription factor, breast cancer | Curtis et al. (2012) |
| 18q21.1             | BCL2  | X         | Cell death, breast cancer | Curtis et al. (2012) |
| 18q21.2             | DCC   | X         | Apoptosis, breast cancer | Koren et al. (2003) |
| 19q13               | AFT5  | X         | Cell cycle progression, breast cancer | Al Sarraj et al. (2005), Watatani et al. (2007) |
| 19q13               | LILRA6| X         | Receptor for class I MHC antigens, breast cancer | Curtis et al. (2012) |
| 19q13               | CYP2A6| X         | Metabolism of pharmaceutical drugs, directly induced by estradiol | Higashi et al. (2007) |
| 19q13               | TGBF1 | X         | Cell division and death, imply in tamoxifen resistance in breast cancer | Achuthan et al. (2001), Popescu & Zimonjic (2002), Jansen et al. (2009), Ivanovic et al. (2006) |
| 19q13               | CEACAM1| X       | Cell survival, differentiation, and growth, breast cancer | Luo et al. (1997), Rietdorph et al. (1997) |
| 20q11.22            | E2F1  | X         | Tumor suppressor gene | Stender et al. (2007) |
| 20q13.1             | CDH4  | X         | Cell adhesion proteins, breast cancer | Curtis et al. (2012) |
| 20q13.1             | MMP9  | X         | Metastasis and cancer cell invasion, breast cancer | Kousidou et al. (2004) |
| 20q13.31            | AURKA | X         | Cell proliferation, breast cancer | Cox et al. (2006) |
| 22q13               | AT4   | X         | Adaptation of cells to stress factors, multidrug resistant gene | Igarashi et al. (2007) |
| 22q13               | SEHL2 | X         | Breast cancer | Curtis et al. (2012) |
| 22q13               | LARGE | X         | Breast cancer | Curtis et al. (2012) |
| 22q13               | XRCC6 | X         | Apoptosis induction, breast cancer | Nik-Zainal et al. (2012) |
Additional new rearrangements were observed after E2 (Fig. 7A, Supplementary Tables 7 and 8) or after TAM treatment (Fig. 7B) at least at two time points. An increase in the frequency of some preexisting chromosomal alterations (\(P \leq 0.01\)) was also observed (Supplementary Tables 7 and 8).

Finally, in SKBR3 (ER\(^-\)/HER2\(^+\)), only 96 h of E2 and TAM treatment significantly increased cell proliferation (\(P < 0.006\) and \(P < 0.024\)) (Fig. 8), as compared with controls. However, de novo chromosomal alterations were already observed after 24 h of treatment. SKBR3 control cells displayed a complex karyotype with a particularly high frequency of chromosome 1 aberrations. After 24 h of E2 and TAM treatment, the karyotype became even more complex with the appearance of new chromosome 1 abnormalities, such as for instance dic(1;19)(p11;q13) and i(1)(q10) (\(P < 0.05\)) (Figs 2, 5D, 8A, B and Supplementary Table 2). A statistically significant increase in the frequency of some pre-existing chromosomal abnormalities was observed in SKBR3 as well (Supplementary Tables 9 and 10).

Expression of hormone receptors following treatment

IHC analysis showed that ER levels remained unchanged after E2 and TAM addition in MCF7, T47D, and SKBR3 cells, whereas in BT474 cells we observed an increase in both ER and PR expression after TAM treatment in parallel with an increase in proliferation (all time points; data not shown). These results support the hypothesis that TAM could play an estrogen agonist role in ER\(^+\)/HER2\(^+\) cells (BT474), as it has been previously suggested (Pietras & Marquez-Garban 2007, Chang 2011, Kumar et al. 2011) and shown in other cell line models (Shou et al. 2004). In addition, increased PR expression in human breast cancers has been associated with TAM resistance (Cui et al. 2005).

E2 addition increased PR expression also in the other ER\(^+\) cell lines (MCF7 and T47D). In contrast, after TAM treatment, a reduced PR expression was observed in MCF7 and T47D cells (data not shown). This is in line with previous observations showing that when estradiol is acting, TAM is not able to increase the level of occupied estrogen receptors and it acts as an anti-estrogen by decreasing the high level of progesterone receptors previously induced by estradiol (Castellano-Diaz et al. 1989).

Discussion

Short-term endocrine treatment has been proposed as an alternative to long-term neoadjuvant therapy to assess tumor response (Dowsett et al. 2007). In addition, low doses of TAM have been proposed for chemoprevention in women at high risk of developing breast cancer (Lazzeroni et al. 2012). Hypersensitivity to low levels of estrogen has been suggested as a potential mechanism of endocrine therapy resistance (Johnston & Dowsett 2003). In addition, residual amounts of estrogen may still be present after treatment with aromatase inhibitors, which function by reducing estrogen biosynthesis (Dowsett 2003).
E2 binding to tubulin may induce a cell cycle arrest in G2/M and generate chromosomal instability (Sato et al. 1992, Sattler et al. 2003, Azuma et al. 2009, Lee et al. 2015).

In this study, we observed that low doses of both E2 and TAM were able to induce structural chromosomal aberrations (deletions, isochromosomes, translocations, and dicentric chromosomes) in both ER+ and ER− breast cancer cells.

Dicentric chromosomes, which contain two functional centromeres, can lead to extensive chromosomal rearrangements, including translocations, dicentric chromosomes, and duplications (Shen 2013, Zhang et al. 2013). Another possible explanation, which can be strictly connected to the previous, is the possibility of clonal selection of the fittest clone (Heng et al. 2006, Liu et al. 2014, Dayal et al. 2015).

When chromosomal alterations were analyzed with respect to proliferation, some specific patterns within each cell line were observed. For instance, T47D cells showed a poorer response to TAM compared with MCF7 cells and mainly displayed numerical chromosomal alterations following treatment. The ER+/HER2+ BT474 cells showed the highest increase in cell proliferation after 24h of treatment with both E2 and TAM compared with control cells. Cell growth increase after TAM treatment may indicate an estrogen agonist activity, possibly enhanced by the co-expression of ER and HER2 (Pietras & Marquez-Garban 2007, Chang 2011, Kumar et al. 2011). Indeed, the cross talk between ER pathways and growth factor receptor...
pathways (EGFR, IGF-1, and HER2) has been involved in cell proliferation, survival, and resistance to endocrine therapy (TAM) in breast cancer (Yager & Davidson 2006, Pietras & Marquez-Garban 2007, Chang 2011). However, in our study, after 48 h of TAM treatment cell proliferation decreased and increased again at 96 h. This decrease/increase may be explained through a clonal selection, with survival of those cells that acquired chromosomal abnormalities fostering proliferative and survival advantages.

As expected, our results confirm that the induction and inhibition of cell proliferation by E2 and TAM, respectively, is dependent on the presence of ER. However, in the ER−/HER2+ SKBR3 cells, these agents induced a high frequency of chromosomal abnormalities and a small increase in proliferative activity at 96 h of treatment. Both effects may be due to the presence of the G protein-coupled receptor30 (GPCR30), an estrogen transmembrane receptor, which modulates both rapid non-genomic and genomic transcriptional events of estrogen (Thomas et al. 2005, Chen & Russo 2009, Li et al. 2010, Cheng et al. 2011). On the other hand, E2 may induce chromatin structural
changes in both ER+ and ER− breast cancer cells through ERR (Hu et al. 2008). The ability of estrogens and its metabolites (catechol estrogens) to induce mutations in cancer cells has been demonstrated both in vivo and in vitro (Liehr 2000, Yager 2015), being observed that estrogens induce overexpression of the Aurora A and B genes (Li et al. 2004), cause genomic instability (Barrett et al. 1981, Tsutsui & Barrett 1997, Ahmad et al. 2000, Jeruss et al. 2003, Lam et al. 2011, Yager 2015), and induce chromosomal aberrations, thus confirming its properties as mutagenic and carcinogenic factor. Along the same lines, in luminal breast tumors, up-regulation of ER signal pathway has been associated with cell proliferation, cell survival, and therapy resistance (Yager & Davidson 2006, Pietras & Marquez-Garban 2007, Chang 2011). Although factors such as local synthesis of estrogen (Fabian et al. 2007), autocrine regulation of cell proliferation (Fabian et al. 2007, Tan et al. 2009), and cross talk with signaling from other growth factors have been associated with this up-regulation, the mechanisms underlying the action of ER are still not fully understood.

In summary, our results demonstrate that low doses of E2 and TAM may favor the production of specific chromosomal abnormalities in both ER+ and ER− breast cancer cells. This genotoxic effect is higher in those cell lines with HER2 gene amplification. The induction of chromosomal alterations by E2 and TAM observed in vitro may support the contention that a careful assessment of the risk and the benefit of E2 and TAM administration should be considered. Indeed, the novel chromosomal rearrangements originated following E2 and TAM exposure may contribute to stimulate cell proliferation leading to survival advantages and allowing for selection of clones with new chromosomal abnormalities. In vivo studies that may help address the biological effect of such alterations and ascertain whether or not these may be responsible for treatment resistance are warranted.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/ERC-16-0078.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was funded by the Italian Association of Cancer Research, AIRC (MFAG13310 to C M), by the Ministry of University (Ex 60% 2014 and 2015 to C M) and by Fondazione Piemontese per la Ricerca sul Cancro (ONLUS) 5 X 1000 Fondi Ministero della Salute 2013 (to A S).

Authors’ contribution statement
M R L performed the experiments and analyzed and interpreted the data. L V d C acquired and analyzed G-banding and M-FISH karyotypes. R R and L A participated in cell culture experiments. T M performed IHC. N R performed statistical analyses and participated in data analysis. I C participated in data analysis. C M and A S conceived and supervised the study and analyzed and interpreted the data. M R L, C M, and A S wrote the manuscript.
Acknowledgements
The authors would like to acknowledge technical support in immunohistochemical and M-FISH analysis by Mrs Maria Stella Scalo, Mrs Stefania Bolla, and Mr Marco Cupo as well as assistance in manuscript preparation by Mrs. Paola Critelli, Mr Jacopo De Gregori, and Mr Lorenzo Di Filippo (Liceo Scientifico Scienze Applicate, Asti).

References

Achuthan R, Bell SM, Roberts P, Leek JP, Horgan K, Markham AF, MacLennan KA & Spiers V 2001 Genetic events during the transformation of a tamoxifen-sensitive human breast cancer cell line into a drug-resistant clone. Cancer Genetics and Cytogenetics 130 166–172. (DOI: 10.1016/S0165-4608(01)00475-7)

Ahmad ME, Shadab GG, Hoda A & Afzal M 2000 Genotoxic effects of estradiol-17beta on human lymphocyte chromosomes. Mutation Research 466 109–115. (DOI: 10.1016/S1383-5718(99)00230-2)

Al Sarraj J, Vinson C & Thiél G 2005 Regulation of asparagine synthetase gene transcription by the basic region leucine zipper transcription factors ATF5 and CHOP. Biological Chemistry 386 873–879. (DOI: 10.1515/BC.2005.102)

Azuma K, Urano T, Horie-Inoue K, Hayashi S, Sakai R, Ouchi Y & Inoue S 2009 Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells. Cancer Research 69 2935–2940. (DOI: 10.1158/0008-5472.CAN-08-3458)

Banham AH, Beasley N, Campo E, Fernandez PL, Fidler C, Gatter K, Jones M, Mason DV, Prime JL, Trougouboff P, et al. 2001 The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Research 61 8820–8829.

Barrett JC, Wagner A & McLachlan JA 1981 Diethylstilbestrol induces neoplastic transformation without measurable gene mutation at two loci. Science 212 1402–1404. (DOI: 10.1126/science.6262919)

Bernstein L & Ross RK 1993 Endogenous hormones and breast cancer risk. Epidemiologic Reviews 15 48–65.

Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Buck G, Chen L, Beare D, Latimer C, et al. 2010 The landscape of somatic copy-number alteration across human cancers. Nature 463 899–905. (DOI: 10.1038/nature08701)

Bertolus V, Katzenellenbogen JA & Katzenellenbogen BS 1986 Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. PNAS 83 2496–2500. (DOI: 10.1073/pnas.83.8.2496)

Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, Buck G, Chen L, Beare D, Latimer C, et al. 2010 Signatures of mutation and selection in the cancer genome. Nature 463 893–898. (DOI: 10.1038/nature08768)

Campiglia M, Pekarsky Y, Menard S, Tagliafu e, Pilotti S & Croce CM 1999 FHT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Research 59 3856–3860.

Castellano-Diaz E, Gonzalez-Quijano MJ, Liminana JM & Diaz-Chico BN 1989 Tamoxifen decreases the estradiol induced progesterone receptors by interfering with nuclear estrogen receptor accumulation. Journal of Steroid Biochemistry 33 133–139. (DOI: 10.1016/0022-4731(89)90036-8)

Chang M 2011 Dual roles of estrogen metabolism in mammary carcinogenesis. BMB Reports 44 423–434. (DOI: 10.5483/ BMBRep.2011.44.7.423)

Chelouche-Lev D, Kluger HM, Berger AJ, Rimm DL & Price JE 2004 alpha-B-crystallin as a marker of lymph node involvement in breast carcinoma. Cancer 100 2543–2548. (DOI: 10.1002/cncr.20304)

Chen JQ & Russo J 2009 E6alpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochimica et Biophysica Acta 1796 162–175. (DOI: 10.1016/j. bbcan.2009.06.003)

Cheng SB, Graeber CT, Quinn JA & Filardo EJ 2011 Retrogрадe transport of the transmembrane estrogen receptor, G-protein-coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the nucleus. Steroids 76 892–896. (DOI: 10.1016/j.steroids.2011.02.018)

Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F & Pasqualini JR 2000 Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. Journal of Steroid Biochemistry and Molecular Biology 72 23–27. (DOI: 10.1006/jsbm.2000.0406)

Cox DG, Hancock SE & Hunter DJ 2006 Polymorphisms of the AURKA (STK15/Aurora Kinase) Gene and Breast Cancer Risk (United States). Cancer Causes and Control 17 81–83. (DOI: 10.1007/s10552-005-0429-9)

Cui X, Schiff R, Arpino G, Osborne CK & Lee AW 2005 Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. Journal of Clinical Oncology 23 7721–7735. (DOI: 10.1200/JCO.2005.09.004)

Cui M, Yu W, Dong J, Chen J, Zhang X & Liu Y 2010 Downregulation of AB1 expression affects the progression and prognosis of human gastric carcinoma. Medical Oncology 27 632–639. (DOI: 10.1007/ s12032-009-9260-6)

Curtis C, Shah SP, Chin SE, Turashvili G, Rueda OM, Dunning M, Speed D, Lynch AG, Samaraiwa S, Yuan Y, et al. 2012 The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486 346–352. (DOI: 10.1038/nature11098)

Dayal J, Albergant L, Newman T & South A 2015 Quantification of multiclonality in control and drug-treated tumour populations using high-throughput analysis of karyotypic heterogeneity. Convergent Science Physical Oncology 1 025001. (DOI: 10.1088/2057-1379/1/2/025001)

Di Modugno F, Mottolese M, Di Benedetto A, Conidi A, Novelli F, Perraccio I, Venturo I, Botti C, Jager E, Santonii A, et al. 2006 The cytoskeleton regulatory protein hMenA (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors. Clinical Cancer Research 12 1470–1478. (DOI: 10.1158/1078-0432.CCR-05-227)

Dos santos I, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanocek S, Clavel-Chapelon F, Feigelson HS, et al. 2010 PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 31 455–461. (DOI: 10.1093/carcin/bgp307)

Dowset M 1999 Drug and hormone interactions of aromatase inhibitors. Endocrine-Related Cancer 6 181–185. (DOI: 10.1677/ erc.0.0060181)

Dowset M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, Salter J, Detre S, Hills M, Walsh G, et al. 2007 Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. Journal of the National Cancer Institute 99 167–170. (DOI: 10.1093/jnci/djk020)

Early Breast Cancer Trials’ Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339 71–85. (DOI: 10.1016/S0140-6736(92)90997-9)

Early Breast Cancer Trials’ Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 1451–1467. (DOI: 10.1016/S0140-6736(97)11423-4)

Early Breast Cancer Trials’ Collaborative Group, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, Mcgale P, Pan HC, Taylor C, et al. 2011 Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378 771–784. (DOI: 10.1016/S0140-6736(11)60993-8)
Edwards AS & Scott JD 2000 A-kinase anchoring proteins: protein kinase A and beyond. Current Opinion in Cell Biology 12 217–221. (doi:10.1016/S0952-683X(00)00126-8)

Fabian CJ, Kimler BF, Zalles CM, Khan QJ, Mayo MS, Phillips TA, Simonsen M, Metheny T & Petroff BK 2007 Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Research and Treatment 106 75–84. (doi:10.1007/s10549-006-9476-5)

Gascoigne KE & Cheeseman IM 2013 Induced dicentric chromosome formation promotes genomic rearrangements and tumorigenesis. Chromosome Research 21 407–418. (doi:10.1007/s10577-013-9368-6)

Greaves M & Maley CC 2012 Clonal evolution in cancer. Nature 481 306–313. (doi:10.1038/nature10762)

Gruuvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, Petersen C, Malmstrom P, Isola J, Borg A, et al. 2007 Estrogen receptor beta expression is associated with tamoxifen response in Ekarh-alpha-negative breast carcinoma. Clinical Cancer Research 13 1987–1994. (doi:10.1158/1078-0432.CCR-06-1823)

Heng HH, Liu G, Bremer S, Ye KJ, Stevens J & Ye CJ 2006 Clonal and non-clonal chromosome aberrations and genome variation and aberration. Genome 49 195–204. (doi:10.1139/G06-023)

Higashi E, Fukami T, Itoh M, Kyo S, Inoue M, Yokoi T & Nakajima M 2007 Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metabolism and Disposition 35 1935–1941. (doi:10.1124/dmd.107.016568)

Hu RJ, Lee MP, Connors TD, Johnson LA, Burn TC, Su K, Landes GM & Maley CC 2004 Clonal and ER-negative breast cancer cells. Journal of Biological Chemistry 283 6752–6763. (doi:10.1074/jbc.M405372200)

Igarashi T, Izumi H, Uchiumi T, Nishio K, Ako T, Tanabe M, Uramoto H, Sugio K, Yasumoto K, Sasaguri Y, et al. 2007 Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 26 4749–4760. (doi:10.1038/sj.onc.1210289)

International Breast Cancer Study Group, Colenien M, Gelber S, Goldhirsh A, Hanks G, Castiglione-Gertsch M, Price KN, Coates AS & Gelber RD 2006 Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-negative breast cancer: International Breast Cancer Study Group Trial 13-93. Journal of Clinical Oncology 24 1332–1341. (doi:10.1200/jco.2005.03.0783)

Ivanovic V, Krtolica K, Krajnovic M & Dimitrijevic B 2006 Role of breast cancer cell karyotypes, E2 and tamoxifen. Breast cancer cell karyotypes, E2 and tamoxifen. Research 23:8 648-649.
Liu G, Stevens JB, Horne SD, Abdallah BY, Ye KJ, Bremer SW, Ye CJ, Chen DJ & Heng HH 2014 Genome chaos: survival strategy during crisis. *Cell Cycle* **13** 528–537. (doi:10.4161/cc.23738)

Ljuslinder I, Malmber, G, Golovleva I, Thomasson M, Grankvist K, Hockenstrom T, Emdin S, Jonsson Y, Hedman H & Henriksson R 2005 Increased copy number at 3p14 in breast cancer. *Breast Cancer Research 7* R719–R727. (doi:10.1186/bcr1279)

Lundgren K, Holm K, Nordenstjeld B, Borg A & Landberg G 2008 Gene products of chromosome 1q1 and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer. *Breast Cancer Research* **10** R81. (doi:10.1186/bcr2150)

Luo W, Wood CG, Earley K, Hung MC & Lin SH 1997 Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains. *Oncogene* **14** 7. (doi:10.1038/sj. onc.1200999)

McGuire WL 1975 Current status of estrogen receptors in human breast cancer. *Cancer* **36** 638–644. (doi:10.1002/1097-0142/197508362<638::aid-cncr2820360805>3.0.co;2-x)

Mizutani A, Okada T, Shibutani S, Sonoda E, Hochegger H, Nishigori C, Miyachi Y, Takeda S & Yamazoe M 2004 Extensive chromosomal breaks are induced by tamoxifen and estrogen in DNA repair-deficient cells. *Cancer Research* **64** 3144–3147. (doi:10.1158/0008-5472.CAN-03-489)

Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ & Roth RA 1999 Up-regulation of Akit in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. *Journal of Biological Chemistry* **274** 21528–21532. (doi:10.1074/jbc.274.31.21528)

Nik-Zainal S, Alexander LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, et al. 2012 Mutational processes molding the genomes of 21 breast cancers. *Cell* **149** 979–993. (doi:10.1016/j.cell.2012.04.024)

O’Brien SI, Fagan A, Fox EJ, Millikan RC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ, et al. 2006 CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. *International Journal of Cancer* **120** 1434–1443. (doi:10.1002/ijc.22413)

Orsetti B, Nogués M, Cervera N, Lasorsa L, Chuchana P, Rouge C, O’Brien SI, Fagan A, Fox EJ, Millikan RC, Brennan DJ, McCann AH, Hegarty S, Moyna S, Duffy MJ, et al. 2007 CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. *Critical Reviews in Oncology/Hematology* **50** 3–22. (doi:10.1016/j.critrevonc.2003.09.003)

Pierantoni GM, Rinaldo C, Mottolese M, Di Benedetto A, Esposito F, Di Benedetto A & Russo IH 2006 The role of estrogen in the initiation of breast cancer. *Endocrine-Related Cancer* **13** 4672–4676. (doi:10.1158/1078-0432.CCR-07-1373)

Quick EL, Parry EM & Parry JM 2008 Do oestrogens induce chromosome specific aneuploidy in vitro, similar to the pattern of aneuploidy seen in breast cancer? *Mutation Research* **651** 46–55. (doi:10.1016/j.mrgentox.2010.07.021)

Rabbits TH 1994 Chromosomal translocations in human cancer. *Nature* **372** 143–149. (doi:10.1038/372143a0)

Radestoš Scaljić, Kjaer SK, Chen LB & Salgia R 2009 Dual action of microtubule drugs on cell cycle and signal transduction pathways in breast cancer cells. *Breast Cancer Research* **10** R71. (doi:10.1186/bcr2136)

Rafii B, Nielsen CF, Andersen SH, Szymański P, Corellé-Termé E, Valé O, Fahrenbacher N, Olsen C J, Daugaard M, Egebjer C, et al. 2012 ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myoeloid zinc finger-1-dependent cathepsin B expression. *Molecular Cell* **45** 764–776. (doi:10.1016/j.molcel.2012.01.029)

Riehlefod L, Lisboa BW, Henkel U, Naumann M, Wagener C & Loning T 1997 Differential expression of CD66a (BGF), a cell adhesion molecule of the carcinoembryonic antigen family, in benign, premalignant, and malignant lesions of the human mammary gland. *Journal of Histochemistry and Cytochemistry* **45** 957–963. (doi:10.1177/00219504970400705)

Rodrigues-Ferreira S, Di Tommaso A, Dimitrov A, Cazaubon S, Gruel N, Colasson H, Nicolas A, Chavoret V, Molinie V, Reyal F, et al. 2009 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. *PLoS ONE* **4** e7239. (doi:10.1371/journal.pone.0007239)

Rondon-Lagos M, Verdin D, Cantogno L, Marchio C, Rangel N, Payan-Gomez C, Gugliotta P, Botta C, Russolati G, Ramirez-Clavijo SR, Pasini B, et al. 2014a Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis. *Molecular Cytogenetics* **7** 8. (doi:10.1186/1755-8166-7-8)

Rondon-Lagos M, Verdin D, Cantogno L, Rangel N, Mele T, Ramirez-Clavijo SR, Scaglotti G, Marchio C & Sapino A 2014b Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells. *Breast Cancer Research* **14** 922. (doi:10.1186/1755-8166-14-922)

Roy D, Calaf GM, Hande MP & Hei TK 2006 Allelic imbalance at 11q23-24 chromosome associated with estrogen and radiation-induced breast cancer progression. *International Journal of Oncology* **28** 667–674. (doi:10.3892/ijo.28.3.667)

Russo J & Russo IH 2006 The role of estrogen in the initiation of breast cancer. *Journal of Steroid Biochemistry and Molecular Biology* **102** 89–96. (doi:10.1016/j.jsbmb.2006.09.004)

Sapino A, Pietribiasi F, Bussolati G & Marchisio PC 1986 Estrogen- and tamoxifen-induced rearrangement of cytoskeletal and adhesion structures in breast cancer MCF-7 cells. *Cancer Research* **46** 2525–2531.

Sato Y, Sakakibara Y, Oda T, Aizu-Yokota H & Ichinoseki K 1992 Effect of estradiol and ethynylestradiol on microtubule distribution in Chinese hamster V79 cells. *Chemical and Pharmaceutical Bulletin* **40** 182–184. (doi:10.1248/cpb.40.182)

Sattler M, Quinnan LR, Pride YB, Gramlich JL, Chu SC, Even GC, Kraeft SK, Chen LB & Salgia R 2003 2-methoxyestradiol alters cell motility, migration, and adhesion. *Blood* **102** 289–296. (doi:10.1182/blood-2003-07-2929)

Scibetta AG, Wong PP, Chan KV, Canosa M & Hurst HC 2010 Dual association by TFAP2A during activation of the p21cip/CDKN1A promoter. *Cell Cycle* **9** 4525–4532. (doi:10.4161/cc.9.22.13746)

Scintu M, Vitale R, Precipe M, Gallo AE, Bonghi L, Valtoti VM, Maiello E, Rinaldi M, Signori E, Rabitti C, et al. 2007 Genomic instability and increased expression of BBUB1 and MAD2L1 genes in ducal breast carcinoma. *Cancer Letters* **254** 298–307. (doi:10.1016/j.canlet.2007.03.021)

Shaffer LG, McGowan-Jordan J & Schmid M 2013 ISCN: *An International System for Human Cytogenetic Nomenclature*. Basel, Switzerland: S. Karger.

Shen MM 2013 Chromoplexy: a new category of complex rearrangements in the cancer genome. *Breast Cancer Research* **23** 567–569. (doi:10.1186/bcr3316)

Shou J, Massarweh S, Osborne CK, Waking AE, Ali S, Weiss H & Schif R 2004 Mechanisms of tamoxifen resistance: increased...
estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. *Journal of the National Cancer Institute* **96** 926–935. (doi:10.1093/jnci/djh166)

Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ & Inoue K 2005 Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. *Molecular and Cellular Biology* **25** 220–232. (doi:10.1128/MCB.25.1.220-232.2005)

Stender JD, Fraser J, Komm B, Chang KC, Kraus WL & Katzenellenbogen BS 2007 Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. *Molecular Endocrinology* **21** 2112–2123. (doi:10.1210/me.2006-0474)

Tan H, Zhong Y & Pan Z 2009 Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines. *BMC Cancer* **9** 31. (doi:10.1186/1471-2407-9-31)

Thomas P, Pang Y, Filardo EJ & Dong J 2005 Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. *Endocrinology* **146** 624–632. (doi:10.1210/en.2004-1064)

Tsutsui T & Barrett JC. 1997 Neoplastic transformation of cultured mammalian cells by estrogens and estrogen like chemicals. *Environmental Health Perspectives* **105** (Supplement 3) 619–624. (doi:10.1289/ehp.97105s3619)

Wang D, Hu L, Zhang G, Zhang L & Chen C 2010 G protein-coupled receptor 30 in tumor development. *Endocrine* **38** 29–37. (doi:10.1007/s12020-010-9363-z)

Watatani Y, Kimura N, Shimizu YI, Akiyama I, Tonaki D, Hirose H, Takahashi S & Takahashi Y 2007 Amino acid limitation induces expression of ATF5 mRNA at the post-transcriptional level. *Life Sciences* **80** 879–885. (doi:10.1016/j.lfs.2006.11.013)

Yager JD 2015 Mechanisms of estrogen carcinogenesis: the role of E2/E1-quinone metabolites suggests new approaches to preventive intervention a review. *Steroids* **99** 56–60. (doi:10.1016/j.steroids.2014.08.006)

Yager JD & Davidson NE 2006 Estrogen carcinogenesis in breast cancer. *New England Journal of Medicine* **354** 270–282. (doi:10.1056/NEJMra050776)

Yong HY, Hwang JS, Son H, Park HI, Oh ES, Kim HH, Kim DK, Choi WS, Lee BJ, Kim HR, et al. 2011 Identification of H-Ras-specific motif for the activation of invasive signaling program in human breast epithelial cells. *Neoplasia* **13** 8. (doi:10.1593/neo.101088)

Zaretsky JZ, Barnea I, Aylon Y, Gorivodsky M, Wreschner DH & Keydar I 2006 MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expression. *Molecular Cancer* **5** 57. (doi:10.1186/1476-4598-5-57)

Zhang CZ, Leibowitz ML & Pellman D 2013 Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangements. *Genes and Development* **27** 2513–2530. (doi:10.1101/gad.229559.113)

Received in final form 8 June 2016
Accepted 29 June 2016
Accepted Preprint published online 29 June 2016